Skip to content

Brain Imaging Studies of the Effects of Cocaine Abstinence

Brain Imaging Studies of the Effects of Cocaine Abstinence

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00581282
Enrollment
0
Registered
2007-12-27
Start date
2005-12-31
Completion date
2005-12-31
Last updated
2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Abuse Disorder

Keywords

Cocaine abstinence, PET scan

Brief summary

This study evaluates theories regarding cocaine abstinence which propose that increased presynaptic and postsynaptic dopamine activity and increased serotonin activity are associated with abstinence in cocaine dependent subjects at the beginning and three to six months after a treatment program. We are using positron emission tomography (PET), Magnetic Resonance Imaging (MRI) and diffusion tensor imaging (DTI) in cortical and subcortical areas in a series of brain imaging studies testing these theories of abnormalities in the dopamine and serotonin system for cocaine addiction by examining the distribution of 18F-fallypride, 18F-altanserin, and FDG. We are evaluating genetic theories associated with cocaine addiction through the examination of genetic markers and functional genomics.

Interventions

RADIATIONPET scan

positron emission tomography PET scan

OTHERfMRI

functional magnetic resonance imaging fMRI

Sponsors

US Department of Veterans Affairs
CollaboratorFED
University of California, Irvine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
21 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

Inclusion criteria include: 1. Subjects must be male or female and English speaking. 2. Subjects must be adults with a history of diagnosis of cocaine dependence disorder (n=20) who are under supervised treatment for dependence or normal control (n=10). 3. Subjects must be between 21 to 65 years of age.

Design outcomes

Primary

MeasureTime frame
PET scans, fMRI scansThe beginning and three to six months after a treatment program

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026